Alkermes ALKS Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Aristada And Aristada Initio | $96.72M-4.5% | $93.82M+27.7% | $97.22M+0.6% | $98.05M+15.8% | $101.3M+17.7% | |
| LUMRYZ | $96.57M— | $39.49M— | —— | —— | —— | |
| LYBALVI | $93.98M+11.5% | $92.36M+31.9% | $94.14M+22.3% | $98.25M+31.5% | $84.28M+18.1% | |
| Vivitrol | $124.45M+2.3% | $112.43M+11.3% | $124.13M-7.5% | $121.13M+6.6% | $121.66M+8.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Alkermes break its business down?
- Alkermes (ALKS) reports revenue by product across 4 parts — Aristada And Aristada Initio, LUMRYZ, LYBALVI and Vivitrol. Each is extracted from the segment footnotes and tracked over time.
- Where does Alkermes's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Alkermes's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
